Comparison Centre
Two compounds, the same questions, no cherry-picking
Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.
Sharing keeps the two compounds you picked.
How to read these scores
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
- Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
- Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
- Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
- Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
- Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
FLGR-242
A branded follistatin-derived protein construct marketed with muscle-growth claims. No FLGR-242-specific animal outcome study, human study or registered human trial has been identified; related evidence is not compound-specific evidence.
IGF-1 LR3
A modified long-acting IGF-1 analogue sold for bodybuilding, and not the same thing as approved IGF-1 medicine.
How far human research has progressed
FLGR-242
Preclinical concept / no compound-specific outcome study identifiedIGF-1 LR3
No adequate human trial evidence for the LR3 analogue itselfClaim-specific benefit evidence
A human exposure study or trial registration does not establish that the claimed benefit occurs.
FLGR-242
Level 1 (theory only). The rationale rests on related constructs (FS I-I, native follistatin and other myostatin inhibitors) and on a patented albumin-binding technology. None of that is FLGR-242-specific outcome evidence and it is not transferred to this profile.
IGF-1 LR3
Not separately assessed; see the full profile.Human research context
FLGR-242
None identified.IGF-1 LR3
No adequate human trial evidence for the LR3 analogue itselfHuman efficacy evidence strength
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
FLGR-242
IGF-1 LR3
Preclinical (animal / lab) evidence strength
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
FLGR-242
IGF-1 LR3
Human safety evidence strength
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
FLGR-242
IGF-1 LR3
Regulatory status (legal position, not proof it works)
FLGR-242
Check jurisdiction-specific details in the profile.
Not an approved medicine anywhere in our record. No FLGR242 or FLGR-242 human trial was found in ClinicalTrials.gov or PubMed searches as of 11 October 2026. Listed under growth-hormone for discoverability only: the claimed mechanism is myostatin/activin-pathway ligand binding, not growth-hormone signalling. Anti-doping context: the WADA 2026 Prohibited List (S4.3) prohibits agents preventing activin receptor IIB activation, explicitly including myostatin-binding proteins such as follistatin; if FLGR-242 functions as claimed it would likely fall in that class. This is a classification note, not evidence that it is clinically active.
IGF-1 LR3
Check jurisdiction-specific details in the profile.
Not an approved medicine in any region. It must not be confused with approved recombinant human IGF-1 (mecasermin), which is licensed for specific rare growth disorders under medical supervision and is a different product with a different evidence base. IGF-1 LR3 is prohibited in sport.
Common claims
FLGR-242
- · Has a 19-day half-life in humans
- · Selectively blocks myostatin without activin effects
- · Builds large amounts of muscle in humans
- · Burns fat or improves metabolic health
IGF-1 LR3
- · Muscle growth and hyperplasia
- · Nutrient partitioning and fat loss
- · Enhanced recovery between training sessions
How settled our evidence rating is
FLGR-242
IGF-1 LR3
Cancer-related questions raised by the biology
These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.
FLGR-242
Unknown. No FLGR-242-specific data exist; growth-pathway interventions warrant study rather than assumption of risk or safety.IGF-1 LR3
Sustained IGF-1 receptor signalling is one of the better-grounded theoretical cancer concerns in this field, given its role in cell proliferation. That is a mechanistic concern, not a demonstrated human risk for this product — and the absence of studies is not reassurance.What this adds up to, in plain English
FLGR-242
This sits in theory and anecdote. Popular claims about it should be treated with very low confidence.IGF-1 LR3
This sits in theory and anecdote. Popular claims about it should be treated with very low confidence.A comparison is not a recommendation